TD Cowen lowered the firm’s price target on Avita Medical (RCEL) to $5.50 from $8 and keeps a Buy rating on the shares. The firm noted Avita Medical is moving through a leadership transition, but the interim CEO is an industry veteran who will focus on a Board-backed plan centered on execution. The roughly $17M preliminary 3Q revenue result underscores that reimbursement friction was real and lasted longer than hoped, but management believes the policy side is largely fixed exiting 3Q.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- Avita Medical’s Strategic Leadership and Product Focus Signal Potential Recovery and Growth
- Avita Medical sees Q3 revenue $17M, consensus $19.2M
- Avita Medical CEO Corbett leaving, Chairman Vance appointed Interim CEO
- Avita Medical downgraded to Hold from Buy at Lake Street
- Avita Medical Appoints Cary Vance as Interim CEO